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AbstrAct
Uncoupled bone resorption leads to net alveolar bone loss in peri-
odontitis. The deficiency of LL-37, the only human antimicrobial 
peptide in the cathelicidin family, in patients with aggressive peri-
odontitis suggests that LL-37 may play a pivotal role in the inhibition 
of alveolar bone destruction in periodontitis. We aimed to investigate 
a novel function of LL-37 in osteoimmunity by blocking osteoclas-
togenesis in vitro. Human osteoclast progenitor cells were isolated 
from a buffy coat of blood samples. The cells were cultured in the 
presence of various concentrations of LL-37 during an in vitro induc-
tion of osteoclastogenesis. Non-toxic doses of LL-37 could block 
multinuclear formation of the progenitor cells and significantly 
diminish the number of tartrate-resistant acid-phosphatase-positive 
cells and the formation of resorption pits (p < 0.05), whereas these 
concentrations induced cellular proliferation, as demonstrated by 
increased expression of proliferating cell nuclear antigen. Expression 
of several osteoclast genes was down-regulated by LL-37 treatment. 
It was demonstrated that nuclear translocation of nuclear-factor-
activated T-cells 2 (NFAT2) was blocked by LL-37 treatment, con-
sistent with a significant reduction in the calcineurin activity (p < 
0.005). Collectively, our findings demonstrate that LL-37 inhibits the 
in vitro osteoclastogenesis by inhibiting the calcineurin activity, thus 
preventing nuclear translocation of NFAT2.
Abbreviations: CALCR, calcitonin receptor; ClC-7, chloride-proton 
exchanger; CTSK, cathepsin K; DAPI, 4′,6-diamidino-2-phenylindole; 
EGTA, ethylene glycol tetraacetic acid; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; M-CSF/CSF1, macrophage-colony- 
stimulating factor; MMP-9, matrix metalloproteinase-9; MTT, [3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]; NFAT2, 
nuclear factor of activated T-cells 2; PBS, phosphate-buffered saline; 
PCNA, proliferating cell nuclear antigen; PCR, polymerase chain reac-
tion; RANK, receptor activator of nuclear factor kappa-B; RANKL, 
receptor activator of nuclear factor kappa-B ligand; RT-PCR, reverse-
transcription polymerase chain-reaction; TBS, Tris-buffered saline; 
TCIRG1, T-cell, immune regulator 1, ATPase, H+ transporting, lyso-
somal V0 subunit A3; TRAcP, tartrate-resistant acid phosphatase.
KEY WOrDs: bone resorption, cathelicidin, innate immu-
nity, nuclear factor of activated T-cells, osteoimmunity, periodontal 
disease.
IntrODuctIOn
LL-37, an antimicrobial peptide of the cathelicidin family, is synthesized by leukocytes and gingival epithelial cells (Dale et al., 2001; Zanetti, 2004). 
Previous studies have demonstrated antimicrobial actions of LL-37 against 
various periodontal micro-organisms (Ouhara et al., 2005; Ji et al., 2007). 
Furthermore, LL-37 displays immunomodulatory properties (Bowdish et 
al., 2006). Other biological actions of LL-37 include angiogenesis (Koczulla 
et al., 2003) and wound-healing promotion by inducing cell proliferation 
(Heilborn et al., 2003; Shaykhiev et al., 2005; Carretero et al., 2008). Some 
human disorders are associated with an aberrant expression of LL-37. For 
example, a morbus Kostman syndrome is caused by the lack of neutrophils 
(Pütsep et al., 2002), resulting in LL-37 deficiency that leads to repeated peri-
odontal infections and severe alveolar bone resorption (Carlsson et al., 2006). 
Similarly, LL-37 cannot be detected in gingival crevicular fluid of patients 
with severe alveolar bone loss in aggressive periodontitis (Puklo et al., 2008). 
It was, therefore, hypothesized that LL-37 might negatively affect osteoclast 
formation and function.
Osteoclasts are derived from hematopoietic cells of monocyte/macrophage 
lineage that are induced by M-CSF (Tanaka et al., 1993) and RANKL (Jimi 
et al., 1999). The activation of dendritic cells derived from the same lineage as 
osteoclasts is inhibited by LL-37 (Kandler et al., 2006). However, it remains 
unknown whether LL-37 may also affect osteoclast formation and function. 
Since LL-37 deficiency is related to aggressive periodontitis, we hypothesized 
that LL-37 might inhibit osteoclastogenesis until LL-37 deficiency would cause 
the severe bone resorption observed in aggressive periodontitis.
MAtErIALs & MEthODs
reagents
The synthesis and authenticity of LL-37 peptide were previously described 
(Montreekachon et al., 2011). Recombinant human M-CSF and RANKL were 
purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Primary anti-
bodies against PCNA and NFAT2 were from Abcam (Cambridge, UK), and 
those against ClC-7 and GAPDH were from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA).
the Antimicrobial Peptide, 
LL-37, Inhibits in vitro 
Osteoclastogenesis
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cell Isolation
Osteoclast progenitor cells were isolated from human peripheral 
blood mononuclear cells (PBMCs). The whole-blood samples 
were obtained from healthy volunteers who provided informed 
consent. The human subject protocol was approved by the Human 
Experimentation Committee, Chiang Mai University. PBMCs 
were directly isolated from the buffy coats by density gradient 
centrifugation with Ficoll-Paque™ (GE Healthcare Bio-Sciences, 
Uppsala, Sweden), when a large number of cells was required. To 
obtain enriched monocytes, we incubated whole blood with anti-
body cocktail (RosetteSep™, STEMCELL Technologies, 
Vancouver, BC, Canada), which crosslinks the unwanted cells 
before density gradient centrifugation. PBMCs were cultured in 
αMEM (Lonza Walkersville, Inc., Walkersville, MD, USA), sup-
plemented with 10% fetal bovine serum (Invitrogen, Carlsbad, 
CA, USA), 2 mM L-glutamine (Lonza Walkersville, Inc.), and 
1% penicillin/streptomycin (Invitrogen). Cells (5 x 105 cells/cm2) 
were seeded on glass coverslips or well plates.
cytotoxicity and cell Proliferation Assays
The cytotoxicity of LL-37 was measured by an MTT assay. 
Enriched monocytes were seeded in 96-well plates (Nunc A/S, 
Roskilde, Denmark) and treated with 25 ng/mL of M-CSF and 
various concentrations of LL-37 for 3 days. Subsequently, a 
20-µL quantity of MTT dye solution (5 mg/mL in PBS) (Sigma-
Aldrich, St. Louis, MO, USA) was added, followed by 200 µL 
of dimethyl sulfoxide to solubilize formazan crystals. The 
absorbance was read at 540 nm with the Titertek Multiskan 
M340 multiplate reader (ICN Flow, Costa Mesa, CA, USA). 
The cell proliferation assay was determined by immunoblotting 
of PCNA expression.
In vitro Osteoclastogenesis and Quantification
Osteoclasts were generated from PBMCs by 25 ng/mL of 
M-CSF and 30 ng/mL of RANKL. Non-toxic concentrations of 
LL-37 (2-8 µM) were chosen to determine the effect of LL-37 
on osteoclastogenesis by TRAcP and F-actin staining. On day 7, 
cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) in 
PBS and stained with 1.5 mM Fast Red Violet LB salt (Sigma-
Aldrich). Subsequently, cells were stained with 20 nM Alexa 
Fluor® 488-conjugated phalloidin (Invitrogen) and 1 µM DAPI 
(Biotium, Inc., Hayward, CA, USA). Stained cells were mounted 
and visualized by a fluorescence microscope (Olympus DP71, 
Tokyo, Japan). TRAcP-positive multinuclear and mononuclear 
cells were manually counted and calculated by ImageJ 1.45g 
software.
In vitro Dentin resorption
To determine the osteoclast function, we performed the resorp-
tion pit assay by culturing PBMCs on dentin slices in 96-well 
chambers with or without LL-37 for 14 days. To detect the 
resorption area, we stained pits with India ink and observed 
them under a microscope. The resorption image was recorded 
and calculated by ImageJ 1.45g software.
rnA Expression
Total RNA was extracted from PBMCs on day 7 by means of an 
Aurum Total RNA Mini kit (Bio-Rad Laboratories, Hercules, CA, 
USA). cDNA was constructed from 250 ng of total RNA with the 
SuperScript First-Strand cDNA System (Fermentas, Hanover, 
MD, USA) (Krisanaprakornkit et al., 2008). A PCR was per-
formed in a reaction mixture, containing specific primer pairs for 
the detection of transcripts of osteoclast genes and GAPDH 
(Appendix A). PCR products were resolved on 1.2% agarose gel 
and stained with ethidium bromide. Photographs were taken by a 
camera attached to a ChemiDoc XRS instrument (Bio-Rad 
Laboratories). A real-time PCR was conducted with the Light 
Cycler-FastStart DNA Master SYBR® Green I system (Roche 
Molecular Biochemicals, Mannheim, Germany) in the LightCycler® 
480 System (Roche Molecular Biochemicals). To compare gene 
expression levels among samples, we calculated the relative gene 
expression from Ct of tested genes, normalized by that of GAPDH. 
The relative Ct (ΔCt) of LL-37-treated samples was compared with 
that of the untreated sample to obtain ΔΔCt.
Immunoblotting
PBMCs underwent lysis in 1% Triton-X100 with protease 
inhibitor cocktail (Roche Molecular Biochemicals). A 10-µg 
quantity of total proteins was separated by 12% SDS-PAGE and 
transferred to nitrocellulose membrane. The membrane was 
blocked with 5% non-fat dry milk in 0.1% Tween-20 (Bio-Rad 
Laboratories) in TBS. The blots were incubated with anti-ClC-7 
(1:1,000), anti-PCNA (1:1,000), and anti-GAPDH (1:500) anti-
body. Immunoreactivity was detected by incubation of the mem-
brane with horseradish-peroxidase-conjugated secondary 
antibody (KPL, Gaithersburg, MD, USA) and LumiGLO 
Reserve Chemiluminescence (KPL). The signal was captured by 
the ChemiDoc XRS instrument.
nuclear and cytoplasmic Extraction
PBMCs cultured with or without 4 or 8 µM of LL-37 for 4 days 
were extracted for nuclear and cytosolic proteins by an NE-PER® 
nuclear and cytoplasmic extraction kit (Pierce, Rockford, IL, 
USA). Ten-µg quantities of nuclear and cytosolic proteins were 
subjected to immunoblotting as described above, with anti-
NFAT2 antibody (1:1,000).
M-csF ELIsA
PBMCs were cultured without exogenously added M-CSF in 
the presence or absence of LL-37 for 3 days. The cell-free cul-
ture supernatants were collected for measurement of M-CSF 
levels by a Quantikine Human M-CSF Immunoassay kit (R&D 
Systems, Inc.) following the manufacturer’s instructions. The 
M-CSF concentrations in supernatants were calculated from the 
standard curve of recombinant human M-CSF.
calcineurin Activity Assay
The calcineurin phosphatase activity in cell lysates was mea-
sured by the colorimetric calcineurin cellular activity assay kit 
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(Enzo Life Sciences International, 
Inc., Plymouth Meeting, PA, USA). 
Briefly, PBMCs were cultured in 
osteoclast medium with or without 
LL-37 for 4 days, and then subjected 
to lysis. Free phosphate and nucleo-
tides in the cell extracts were removed 
by de-salting gel filtration. The phos-
phatase activity of calcineurin was 
determined from free phosphate 
released from RII phosphopeptide 
based on the classic Malachite green 
assay. Human recombinant calcineu-
rin was used as a positive control.
Immunofluorescence
PBMCs were fixed with 4% parafor-
maldehyde in PBS and incubated 
overnight at 4°C with anti-NFAT2 
antibody. The localization of NFAT2 
was detected by NorthernLights™ 
557 anti-rabbit IgG (R&D Systems, 
Inc.) and co-stained with Alexa 
Fluor® 488-conjugated phalloidin and 
DAPI.
statistical Analysis
Data were compared by mean ± stan-
dard deviation. To determine the dif-
ferences among samples, we analyzed 
the variances by independent t test, 
with statistical significance levels at 
p < 0.05, p < 0.01, and p < 0.005.
rEsuLts
LL-37 Promotes cell Proliferation
We began our study by culturing 
enriched monocytes in osteoclast 
medium with LL-37. It was found 
that the monocytes did not differenti-
ate into multinucleated osteoclasts (arrows) in the presence of 
LL-37 (Fig. 1A). The monocytes did not survive without the 
addition of M-CSF, whereas, surprisingly, they maintained their 
viability upon treatment with only LL-37 (Fig. 1A). To investi-
gate the cytotoxicity of LL-37, we treated enriched monocytes 
with LL-37 from 2 to 30 µM. The cells mostly died if they were 
exposed to 20 µM (Fig. 1B), consistent with the significant 
decrease in viable cells, treated with 20 and 30 µM (Fig. 1C). 
However, low doses of LL-37 (2-6 µM) appeared to signifi-
cantly increase the number of viable cells (Fig. 1C), confirmed 
by up-regulated PCNA expression in PBMCs, treated with 2 to 
10 µM of LL-37 (Fig. 1D). M-CSF levels in cell-free culture 
supernatants of PBMCs were raised by LL-37 treatment, and the 
significance level was reached by treatment with 8 µM of LL-37 
(Fig. 1E), indicating that LL-37 induces M-CSF production and 
secretion in PBMCs and maintains the cell viability even with-
out exogenously added M-CSF.
LL-37 Inhibits in vitro Osteoclastogenesis and Down-
regulates Expression of Osteoclast Genes
To determine the effect of LL-37 on osteoclastogenesis, we exam-
ined TRAcP and F-actin staining and the expression of osteoclast 
genes. Mature osteoclasts were generated in vitro from enriched 
monocytes on day 7 in the presence or absence of LL-37. LL-37 
inhibited osteoclast formation by diminishing TRAcP and F-actin 
staining in a dose-dependent manner (Figs. 2A and 2B, respec-
tively). The TRAcP-positive multinuclear and mononuclear cells 
Figure 1. LL-37 inhibits osteoclastogenesis, but promotes proliferation of PBMCs by M-CSF 
induction. (A) TRAcP staining on in vitro-generated osteoclasts under RANKL stimulation with (+) 
or without (–) M-CSF and 4 µM of LL-37 for 7 days. The mature osteoclasts (arrows) are large cells 
that exhibit TRAcP. (b) TRAcP staining on viable PBMCs after being incubated with M-CSF and 
indicated doses of LL-37 for 3 days. Magnification power = 20x (c) MTT assay. PBMCs were 
incubated with M-CSF and indicated doses of LL-37 for 3 days. The linear graph demonstrates the 
ratios of cell viability in LL-37-treated samples relative to the untreated control, whose ratio was 
set to 1 (error bar = SD, *p < 0.05, **p < 0.01, ***p < 0.005, n = 9). (D) Immunoblot detection 
of PCNA and GAPDH expression in PBMCs treated with M-CSF and various LL-37 concentrations 
for 4 days. The data in A, B, and D are representative of 3 independent experiments. (E) M-CSF 
ELISA. PBMCs, cultured in the absence of exogenously added M-CSF, were treated with 0, 4, or 
8 µM of LL-37 for 3 days. The cell-free culture supernatants were analyzed for M-CSF 
concentrations in pg/mL (error bar = SD, *p < 0.05, n = 4).
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were counted, and their ratios were significantly decreased by 
LL-37 treatment in a dose-dependent fashion compared with the 
untreated control, suggesting that LL-37 blocks both TRAcP 
expression and osteoclast fusion (Fig. 
2C). From the time-course study, the sig-
nificant inhibition of LL-37 on the forma-
tion of TRAcP-positive multinuclear cells 
was observed when LL-37 was added 
from days 0 to 4 (Appendix B). However, 
when LL-37 was added on day 6, no sig-
nificant inhibition on TRAcP-positive 
cells was observed (Appendix B), sug-
gesting that LL-37 negatively affects the 
early stage of osteoclastogenesis (days 
0-4). To determine the inhibitory effect of 
LL-37 on osteoclast gene expression, we 
performed real-time PCR analyses. LL-37 
significantly inhibited expression of 
MMP-9, TCIRG1, NFAT2, RANK, 
CALCR, and CTSK mRNAs in a dose-
dependent manner, whereas it induced 
M-CSF/CSF1 expression (Fig. 2D). Since 
ClC-7 is required for osteoclasts to resorb 
mineralized tissue, this protein is sug-
gested to be one of osteoclast markers 
(Kornak et al., 2001). The expression of 
ClC-7 protein in PBMC lysates was deter-
mined, and the finding showed down-
regulation of ClC-7 expression by LL-37 
in a dose-dependent manner (Fig. 2E).
LL-37 Inhibits Dentin resorption
To examine the effect of LL-37 on osteo-
clast function in vitro, we seeded 
enriched monocytes and induced cell dif-
ferentiation in the presence or absence of 
LL-37 on dentin slices. The quantity of 
pits on the dentin slices was decreased 
by LL-37 treatment (Fig. 3A). The ratio 
of pit formation significantly declined in 
the LL-37-treated samples compared with that in the untreated 
sample (Fig. 3B).
LL-37 Prevents nuclear translocation of nFAt2 by 
Inhibiting calcineurin Activity
To investigate the inhibitory mechanism of LL-37, we deter-
mined whether LL-37 could affect the function of NFAT2, a 
master transcription factor for many osteoclast genes, including 
itself (Chuvpilo et al., 2002). The NFAT2 was localized in the 
cytoplasm of LL-37-treated PBMCs compared with the local-
ization of NFAT2 in the nuclei of untreated PBMCs (Fig. 4A), 
indicating that LL-37 blocks nuclear translocation of NFAT2. 
The immunoblot analyses confirmed the absence of NFAT2 in 
the nuclear extract of PBMCs treated with LL-37, whereas sev-
eral immunoreactive bands of NFAT2 (around 80-100 kDa) 
were detected in the cytosolic extracts, consistent with a previ-
ous finding (Garcia-Gomez et al., 2012) (Fig. 4B). Accordingly, 
LL-37 treatment significantly inhibited NFAT2 mRNA expres-
sion in a dose-dependent manner, as determined by RT-PCR and 
Figure 2. LL-37 inhibits in vitro osteoclastogenesis. Representative images from 5 separate 
experiments of differentiated cells induced by M-CSF and RANKL with or without indicated 
concentrations of LL-37 for 7 days and observed by (A) TRAcP staining and immunocytochemistry 
of PCNA under a light microscope and (b) TRAcP (red), F-actin (green), and DAPI staining 
under a fluorescence microscope. Bar = 100 µm. (c) The bar graph demonstrates the ratios 
of multinuclear (dark gray bars) and of mononuclear (light gray bars) TRAcP-positive cells in 
LL-37-treated samples relative to the untreated sample, whose ratio was set to 1 (error bar = 
SD, *p < 0.05, **p < 0.01, ***p < 0.005, n = 5). (D) The bar graph shows the percentages 
of CSF1, MMP-9, TCIRG1, NFAT2, RANK, CALCR, and CTSK mRNA expression in LL-37-
treated samples (dark gray and light gray bars for 4 and 8 µM of LL-37, respectively) relative 
to the percentage of gene expression in the untreated sample (black bars), set to 100% (error 
bar = SD, *p < 0.05, **p < 0.01, ***p < 0.005, n = 4). (E) Immunoblot detections of ClC-7 
and GAPDH in PBMC lysates during osteoclast induction in the presence or absence of 
indicated doses of LL-37 for 7 days. Note an intense band around 60 kDa from immunoreaction 
with anti-ClC-7 polyclonal antibody. The image is representative of 3 separate experiments.
Figure 3. LL-37 inhibits in vitro dentin resorption. (A) Representative 
images from 7 independent experiments of dentin slices show 
resorption pits, formed by in vitro-generated osteoclasts for 14 days 
with 0, 4, or 8 µM of LL-37. Bar = 200 µm. (b) The bar graph shows 
the relative ratios of the quantity of resorptive areas in LL-37-treated 
samples to the untreated control, whose ratio was set to 1 (error bar = 
SD, *p < 0.05, **p < 0.01, n = 7).
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real-time PCR (Figs. 4C and 4D, respec-
tively). To verify the blockade of NFAT2 
nuclear translocation by LL-37, we mea-
sured the activity of calcineurin, controlling 
dephosphorylation of NFAT2, in LL-37-
treated and untreated PBMCs. It was found 
that LL-37 treatment could significantly 
decrease the calcineurin activity around 
50% compared with the untreated control 
(Fig. 4E).
DIscussIOn
LL-37 exerts an inhibitory effect on in vitro 
osteoclastogenesis, as evidenced by the 
inhibition of multinuclear formation, TRAcP 
expression, and resorption pit formation, 
down-regulating osteoclast-specific gene 
expression, suppressing the calcineurin 
activity, and then blocking NFAT2 nuclear 
translocation. To the best of our knowledge, 
this is the first detailed analysis of the 
inhibitory action on in vitro osteoclastogen-
esis of LL-37. Furthermore, low doses of 
LL-37 can increase proliferation of undif-
ferentiated monocytes, as evidenced by 
induced PCNA expression. M-CSF is an 
essential molecule that promotes the prolif-
eration of osteoclast progenitors (Tanaka 
et al., 1993), and M-CSF-deficient mice 
demonstrate an osteopetrotic phenotype due 
to the lack of osteoclasts (Umeda et al., 
1996). Our study has demonstrated that 
M-CSF expression is enhanced by LL-37 in 
PBMCs, consistent with the inducible effect 
of LL-37 on M-CSF expression in the 
monocytic cell line RAW264.7 (Scott et al., 
2002). Therefore, LL-37 possibly maintains 
the viability of PBMCs by enhancement of 
M-CSF production. Our findings also corre-
spond well with the previously reported func-
tion of M-CSF and LL-37 as anti-apoptotic 
molecules (Woo et al., 2002; Chamorro 
et al., 2009).
The concentrations of LL-37 less than 10 
µM were not toxic to PBMCs, but the sig-
nificant cell death was found at 20 µM or 
greater. This is in line with the finding that 
shows general toxicity of LL-37 to eukary-
otic cells at concentrations above 13 µM 
(Johansson et al., 1998). Low LL-37 con-
centrations have been recently described to 
convert monocytes to a special cell type 
capable of mineralization, called mono-
osteophils (Zhang and Shively, 2010). 
Instead of resorption pit formation, von 
Figure 4. LL-37 blocks nuclear translocation of NFAT2 by decreasing the calcineurin 
activity. PBMCs were cultured in osteoclast medium, containing M-CSF with (+) or without 
(–) RANKL, as a negative control, in the presence or absence of indicated doses of LL-37 
for 4 days. (A) Cells were stained with NFAT2 (red), F-actin (green), and DAPI (blue), and 
observed under a fluorescence microscope. Note no nuclear and weak cytoplasmic 
staining of NFAT2 in the PMBC culture without RANKL activation (the left-most column). 
Note the punctate staining of F-actin in PBMCs. Bar = 50 µm. (b) The nuclear and cytosolic 
protein fractions were extracted, subjected to immunoblotting, and probed with anti-NFAT2 
antibody. Note the absence of immunoreactive bands in the nuclear and cytosolic extracts 
of PBMCs without RANKL activation (the left-most lane), consistent with the finding in (A). 
Further, the presence of several immunoreactive bands in the cytosolic extract may suggest 
post-translational modification of NFAT2. The findings in (A) and (B) are representative of 
3 separate experiments. (c) An RT-PCR analysis. Total RNA was extracted from PBMCs, 
cultured in osteoclast medium with or without indicated doses of LL-37 for 4 days. –RT is a 
sample where the reverse-transcriptase enzyme was omitted in the reaction. (D) A real-time 
PCR analysis of NFAT2 expression was conducted with cDNA from (C). The bar graph 
illustrates the relative ratios (ΔΔCt) of LL-37-treated samples to that of the untreated sample, 
set to 1 (error bar = SD, **p < 0.01, n = 4). (E) The calcineurin activity assay. PBMCs 
were cultured in osteoclast medium, containing 0, 4, or 8 µM of LL-37 for 4 days, and 
then underwent lysis. The bar graph shows the percentages of calcineurin activity in 
LL-37-treated samples relative to that of the untreated sample, set to 100% (error bar = SD, 
***p < 0.005, n = 4).
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Kossa-positive material was detected in monocytes incubated 
with LL-37 besides M-CSF and RANKL. The effect of LL-37 
on osteoclastogenesis, however, was not characterized. The 
interpretation of these findings is currently very difficult. In our 
hands, there was no evidence for enhanced mineral deposition 
by monocytes under these conditions, which might be due to 
different culturing conditions.
The number of multinuclear cells is decreased, if the osteo-
clast formation is induced in the presence of LL-37, suggesting 
that non-toxic doses of LL-37 can block cell fusion of mono-
cytes. It has been demonstrated that extracellular adenosine 
facilitates cell fusion by activating purinergic P2X7 receptor 
(Pellegatti et al., 2011). The P2X7 directs a release of adenosine 
triphosphate, which is degraded to adenosine and enhances cell 
fusion. Therefore, the P2X7 receptor may be a candidate recep-
tor for the inhibitory effect of LL-37 on osteoclastogenesis. 
However, from our study, the P2X7 does not appear to act as a 
target receptor for the inhibition of cell fusion, since treatment 
with the neutralizing antibody against P2X7 did not reverse the 
inhibition of osteoclastogenesis by LL-37 (Appendix C). 
Consequently, the candidate receptor for the inhibitory effect of 
LL-37 on osteoclastogenesis remains to be further investigated.
NFAT2 is the master regulator of osteoclastogenesis by tran-
scribing many osteoclast-specific genes. Osteoclastogenesis 
requires NFAT2 nuclear translocation activated by RANKL that 
induces the calcineurin activity (Takayanagi et al., 2002). We 
have shown that LL-37 significantly decreases the calcineurin 
activity, resulting in the blockade of NFAT2 nuclear transloca-
tion and the down-regulation of mRNA expression for several 
osteoclast genes, including NFAT2. Consequently, we propose 
that the calcineurin-NFAT2 axis is a critical signaling pathway 
for the inhibition of in vitro osteoclastogenesis by LL-37.
In the oral cavity, the levels of LL-37 expression in tissues 
from aggressive periodontitis are lower than those from chronic 
periodontitis (Türkoğlu et al., 2011). This finding is consistent 
with ours, showing a novel inhibitory effect of LL-37 on osteo-
clastogenesis. We postulate that LL-37 is involved in bone 
metabolism during rapid bone destruction in aggressive periodon-
titis. Nevertheless, our in vitro findings should be interpreted with 
caution, since it is imperative to study the inhibition of in vivo 
osteoclastogenesis by LL-37 before any possible application of 
LL-37 in the therapeutic management of aggressive periodontitis.
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